Development of vaccines against hepatitis A and hepatitis B - PubMed

Review

Development of vaccines against hepatitis A and hepatitis B

A A McLean. Rev Infect Dis. 1986 Jul-Aug.

Abstract

Hepatitis A and hepatitis B are viral infections of the liver. Hepatitis A is spread by the fecal-oral route--i.e., by ingestion of virus shed in the stool of acutely infected individuals. The virus is transmitted from person to person or (in outbreaks) via contaminated food or water. Population groups at increased risk of acquiring hepatitis A include children and staff in day care centers. Hepatitis B is spread by blood and other body fluids from acutely infected individuals or chronically infected carriers. Infection occurs when virus contained in these fluids enters the body through mucosal surfaces or breaks in the skin. A vaccine against hepatitis B has been developed. It consists of noninfectious hepatitis B surface antigen purified from the plasma of chronic carriers. The three sequential inactivation treatments used in manufacture of the vaccine kill hepatitis B virus and other infectious agents that may be present in human plasma, including the human T cell-lymphotropic virus that causes the acquired immunodeficiency syndrome. The vaccine is well tolerated, highly immunogenic, and highly effective in preventing hepatitis B. Both live attenuated and killed vaccines against hepatitis A are also being investigated. A live attenuated vaccine is preferred and seems feasible on the basis of initial studies in animals and volunteers.

Similar articles

• Vaccines to prevent hepatitis B and hepatitis A virus infections.

  Hadler SC. Hadler SC. Infect Dis Clin North Am. 1990 Mar;4(1):29-46. Infect Dis Clin North Am. 1990. PMID: 2155262 Review.

• Studies of prototype live hepatitis A virus vaccines in primate models.

  Karron RA, Daemer R, Ticehurst J, D'Hondt E, Popper H, Mihalik K, Phillips J, Feinstone S, Purcell RH. Karron RA, et al. J Infect Dis. 1988 Feb;157(2):338-45. doi: 10.1093/infdis/157.2.338. J Infect Dis. 1988. PMID: 2826614

• [Viral hepatitis and immunoprophylaxis].

  Deinhardt F, Jilg W. Deinhardt F, et al. Zentralbl Bakteriol Mikrobiol Hyg B. 1985 Feb;180(2-3):134-45. Zentralbl Bakteriol Mikrobiol Hyg B. 1985. PMID: 2986380 Review. German.

• Hepatitis virus vaccines: present status.

  Krugman S. Krugman S. Yale J Biol Med. 1982 May-Aug;55(3-4):375-81. Yale J Biol Med. 1982. PMID: 6295013 Free PMC article. Review.

• Towards a hepatitis A vaccine. A review.

  Anderson BN, Coulepis AG, Gust ID. Anderson BN, et al. J Hyg (Lond). 1984 Oct;93(2):269-76. doi: 10.1017/s0022172400064792. J Hyg (Lond). 1984. PMID: 6094664 Free PMC article. Review. No abstract available.

Cited by

• From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.

  Kajal, Pandey A, Mishra S. Kajal, et al. 3 Biotech. 2024 Oct;14(10):242. doi: 10.1007/s13205-024-04075-7. Epub 2024 Sep 22. 3 Biotech. 2024. PMID: 39319014 Review.

• Hepatitis B vaccination with short dose intervals--a possible alternative for post-exposure prophylaxis?

  Wahl M, Hermodsson S, Iwarson S. Wahl M, et al. Infection. 1988 Jul-Aug;16(4):229-32. doi: 10.1007/BF01650758. Infection. 1988. PMID: 2972628 Clinical Trial.

• Policies for control of communicable disease in day care centres.

  Chouillet A, Maguire H, Kurtz Z. Chouillet A, et al. Arch Dis Child. 1992 Sep;67(9):1103-6. doi: 10.1136/adc.67.9.1103. Arch Dis Child. 1992. PMID: 1417054 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information